Literature DB >> 8540856

Empirical or culture-guided therapy for microbial keratitis? A plea for data.

P J McDonnell1.   

Abstract

In the United States, about 30,000 bacterial corneal ulcers are treated annually. Compared with 100, or even 20, years ago ophthalmologists today have available to them many diagnostic tools (including special media and bacterial identification techniques), and in impressive assortment of antibiotics. Many reviews and book chapters describe the uses of microbiologic studies--from Gram and Giemsa staining to media inoculation to immunofluorescence and even molecular genetics--to identify causative organisms. This literature also describes the formulas for preparation of highly concentrated, "fortified" antibiotics for initial treatment of bacterial keratitis, until culture and sensitivity results are available to guide modifications in therapy. It would seem, therefore, that "experts" in the field of corneal and external diseases have reached consensus on an appropriate initial microbiologic evaluation and treatment of suspected microbial keratitis, and the large body of literature on this topic might be considered to represent practice guidelines. It comes as a surprise to many that these published "guidelines" apparently are routinely ignored in current clinical practice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8540856     DOI: 10.1001/archopht.1996.01100130080013

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  19 in total

1.  Initial therapy for suppurative microbial keratitis in Iraq.

Authors:  Faiz Al-Shakarchi
Journal:  Br J Ophthalmol       Date:  2007-06-27       Impact factor: 4.638

2.  Corneal ulceration in the elderly in Hyderabad, south India.

Authors:  D Y Kunimoto; S Sharma; P Garg; U Gopinathan; D Miller; G N Rao
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

3.  Microbial keratitis following vegetative matter injury.

Authors:  Mukesh Taneja; Jatin N Ashar; Anurag Mathur; Suma Nalamada; Prashant Garg
Journal:  Int Ophthalmol       Date:  2012-10-06       Impact factor: 2.031

4.  Topical pefloxacin in bacterial keratitis.

Authors:  R B Vajpayee; N Sharma; B Verma; M Vajpayee; S K Gupta; G Satpathy; R Saxena
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

5.  The clinical differentiation of bacterial and fungal keratitis: a photographic survey.

Authors:  Cyril Dalmon; Travis C Porco; Thomas M Lietman; N Venkatesh Prajna; Lalitha Prajna; Mano Ranjan Das; J Arun Kumar; Jeena Mascarenhas; Todd P Margolis; John P Whitcher; Bennie H Jeng; Jeremy D Keenan; Matilda F Chan; Stephen D McLeod; Nisha R Acharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-02       Impact factor: 4.799

6.  Clinical Features, Antibiotic Susceptibility Profiles, and Outcomes of Infectious Keratitis Caused by Achromobacter xylosoxidans.

Authors:  Oriel Spierer; Pedro F Monsalve; Terrence P OʼBrien; Eduardo C Alfonso; Daniel Gologorsky; Darlene Miller
Journal:  Cornea       Date:  2016-05       Impact factor: 2.651

7.  The clinical diagnosis of microbial keratitis.

Authors:  Matthew A Dahlgren; Ahila Lingappan; Kirk R Wilhelmus
Journal:  Am J Ophthalmol       Date:  2007-04-03       Impact factor: 5.258

8.  Simplifying collection of corneal specimens in cases of suspected bacterial keratitis.

Authors:  Stephen B Kaye; Prasad G Rao; Godfrey Smith; John A Scott; Sharon Hoyles; Clare E Morton; Colin Willoughby; Mark Batterbury; Graham Harvey
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

9.  A management dilemma: infectious keratitis associated with soft contact lens use and dubious treatment compliance.

Authors:  Konstantinos T Tsaousis; Georgios Sakkias; Nikolaos Kozeis; Periklis Tahiaos
Journal:  Case Rep Med       Date:  2010-08-10

10.  Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases.

Authors:  T Bourcier; F Thomas; V Borderie; C Chaumeil; L Laroche
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.